anticoagulants, vitamin K antagonists, antiplatelet drugs, aspirin, clopidogrel, bleeding risk
DISEASE INTERVENTION COMPARISON RESULTS
Arch Intern Med. 2010 Sep 13;170(16):1433-41 Cohorts
IN anticoagulants, vitamin K antagonists, antiplatelet drugs, aspirin, clopidogrel, bleeding risk The Use of
aspirin and/or clopidogrel associated to warfarin
As Treatment, Chronic
Is worse Than
warfarin alone
To risk of fatal and nonfatal bleeding: 14% per patient-year with warfarin plus clopidogrel, 16% with warfarin plus aspirin plus clopidogrel
Circulation. 2012 Sep 4;126(10):1185-93 Cohorts
IN anticoagulants, vitamin K antagonists, antiplatelet drugs, aspirin, clopidogrel, bleeding risk The Use of
vitamin K antagonist (VKA) +aspirin +clopidogrel
As Treatment, Chronic
Is worse Than
vitamin K antagonist +1 antiplatelet, or dual antiplatelet therapy with aspirin +clopidogrel
To cause bleeding events, specially in the first 30-90 days: 23 events per 100 person-years with triple therapy, 20 with VKA +1 antiplatelet, 14 with dual antiplatelet. Triple therapy was not more effective than VKA +1 antiplatelet